Literature DB >> 23895640

Orbital richter syndrome.

Hayyam Kiratli1, Berçin Tarlan, Salih Uzun, Özlem Tanas, Ayşegül Uner.   

Abstract

We report two patients with previously diagnosed chronic lymphocytic leukemia who developed Richter syndrome in the orbit as the sole extranodal site. The medical history, clinical findings, orbital imaging and histopathological features of the patients were reviewed. Treatment protocols and the outcomes were also assessed. The first patient developed Richter syndrome at the age of 64 years, 3 years after the diagnosis of chronic lymphocytic leukemia. The tumor was located at the inferotemporal quadrant of the orbit. The second patient was 59 years old when Richter syndrome arose in the lacrimal gland, 4 years after the diagnosis of chronic lymphocytic leukemia. Incisional biopsy from the orbital tumors were performed. Histopathological findings included diffuse CD20, CD 23, CD5, bcl2, bcl6 positive lymphocytic infiltration. Both patients were treated with chemotherapy and rituximab. During 3 years of follow-up, there was no orbital or systemic recurrence of the disease. Richter syndrome may develop in the orbital soft tissue and the lacrimal gland, and the orbital disease appears to have a better prognosis compared to patients with systemic involvement.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23895640     DOI: 10.3109/01676830.2013.815223

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  2 in total

1.  Rare primary presentation of chronic lymphocytic leukemia as chronic orbital space occupying lesion.

Authors:  Vaibhav Kumar Jain; Usha Singh; Gaurav Prakash; Rakesh Kumar Vashishta; Vaneet Singh
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

2.  CLL: Common Leukemia; Uncommon Presentations.

Authors:  Deepesh Lad; Pankaj Malhotra; Neelam Varma; Manupdesh Singh Sachdeva; Ashim Das; Radhika Srinivasan; Amanjit Bal; Alka Khadwal; Gaurav Prakash; Vikas Suri; Savita Kumari; Sanjay Jain; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-24       Impact factor: 0.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.